Q-omics provides the consensus-scored TOMM22P5 profile across patient tissues and cancer cell-line models. TOMM22P5 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TOMM22P5 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, TOMM22P5 RNA expression shows 5,158 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight BLCA, COAD, and UCEC as cancer lineages where TOMM22P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOMM22P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOMM22P5 survival associations across molecular data types. TOMM22P5 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOMM22P5 RNA expression–survival associations across cancer types. High TOMM22P5 expression shows unfavorable associations in BLCA, KICH, MESO and THCA, but favorable associations in UCS and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for TOMM22P5 RNA expression.
This table summarizes TOMM22P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TOMM22P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOMM22P5 shows lower tumor expression in PAAD and higher tumor expression in COAD, HNSC, PRAD, STAD and LIHC. The COAD box plot shows higher TOMM22P5 RNA expression in tumor versus normal tissue (log2 FC = +0.228, t-test p = .001).
This table shows molecular features associated with TOMM22P5 in patient tissues and cancer cell lines. In patient samples, TOMM22P5 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
